Austrianova announces the publication of a peer-reviewed article on the use of implanted Cell-in-a-Box encapsulated cells for the sustained production of the anti-aging protein Klotho in patients

by Walter Gunzburg | Oct 31, 2026 | Press Release

Brian Salmons, Austrianova’s CEO added “This publication provides the background and future perspectives for our ongoing collaboration with Avaí Bio through our joint venture company, Klothonova.  This press release can be viewed online...

Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale SanRaffaele for Diabetes Cell Therapy Program

by Walter Gunzburg | Oct 8, 2026 | News, Press Release

This press release can be viewed online at: https://www.globenewswire.com/news-release/2026/10/07   LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) — Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today...

Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference

by Walter Gunzburg | Sep 26, 2026 | News, Press Release

This press release can be viewed online at: https://ir.avaibio.com/press-releases/2026/avai-bio-and-austrianova-present-encapsulated-cell-approach-to-sustained-klotho-delivery-at-2026-klotho-conference Watch Austrianova Founder & CTO, Prof. Walter Gunzburg...

Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes

by Walter Gunzburg | Aug 13, 2026 | Press Release

This press release can be viewed online at: https://www.globenewswire.com/news-release/2026/08/12/3343647https://www.einpresswire.com/article/634030792/ Agreement combines Austrianova’s Cell-in-a-Box® technology with San Raffaele Hospital’s stem cell-derived beta cell...

Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies

by Walter Gunzburg | Nov 19, 2025 | News, Press Release

LAS VEGAS, NEVADA, November 18, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced that its 50/50 joint venture...

Avant Technologies and Austrianova Sign Joint Venture, Licensing Agreement to Advance Klotho-Based Therapies

by Walter Gunzburg | Sep 19, 2025 | News, Press Release

LAS VEGAS, Sept. 18, 2025 /PRNewswire/ — Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a Nevada-based corporation, and Austrianova (SGAustria Pte. Ltd.), a Singapore-based biotechnology leader, today announced the...